STA
MYGN icon

Summit Trail Advisors’s Myriad Genetics MYGN Stock Holding History

Summit Trail Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-1,350
Closed -$50K – 390
2018
Q2 		$50K Buy
+1,350
New +$45.6K 0.02% 306
2018
Q1 		– Sell
-1,840
Closed -$70K – 1222
2017
Q4 		$70K Buy
+1,840
New +$62.1K 0.01% 728

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Summit Trail Advisors's MYGN Position: Q3 2018 in Review

Summit Trail Advisors sold out of Myriad Genetics (MYGN) in Q3 2018, closing a stake of 1,350 shares — an estimated $50K sold.

Summit Trail Advisors first reported a position in MYGN in Q4 2017 and held it in 2 quarters. The position peaked at $70K in Q4 2017. 284 funds tracked by Wall St. Rank hold MYGN as of Q3 2018.

  • Summit Trail Advisors reported no remaining Myriad Genetics position as of Q3 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 1,350 Myriad Genetics shares in Q3 2018, an estimated $50K.
  • Summit Trail Advisors first reported a position in Myriad Genetics in Q4 2017 and held it in 2 quarters.
  • Summit Trail Advisors's Myriad Genetics position peaked at $70K in Q4 2017.
  • 284 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2018.

Based on Summit Trail Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.